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Abstract 
Tourette’s syndrome (TS) is a neuro-behavioral disease associated by phonic 
and motor tics with a high frequency of psychiatric co-morbidities. For these 
cases, deep brain stimulation (DBS) is a developing neuro-modulated treatment 
option since the first report on a successful surgery in 1999. A male thirty-one 
years old (77 kg, 178 cm) with diagnosis of Gilles De La Tourette syndrome 
admitted to neurosurgery ward. His medication included Aripiprazole, 
pimozide, buspirone, clomipramine, citalopram, phenytoin, Desmopressin and 
Lithium. The patient underwent implanting DBS (Deep Brain Stimulator) 
surgery and battery implantation in two steps with two weeks interval. General 
anesthesia with considerations and according to behavior of disease and drug 
interactions was performed. The cause and symptoms may be due to central 
dopaminergic hyperactivity or anomalous dopamine neurotransmission and 
interventions and anesthesia should be done considering these abnormalities. 
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Introduction 
Tourette’s syndrome (TS) is a behavioral and 
neural disease associated by phonic and motor tics with 
a high frequency of psychiatric sign and symptoms like 
attention and activity co-morbidities, autism and  
impulse control (1). The onset is primarily in childhood 
and the symptoms may disappear or necessitate with 
pharmacological therapies linked with cognitive-
behavior therapies (2). 
Although symptoms usually diminish by 
adulthood, some of patients continue to experience 
symptoms during life that in severe cases fail to 
respond to standard medical and behavioral therapies 
(3). For these cases, deep brain stimulation (DBS) is a 
developing treatment option since the first report on a 
successful surgery in 1999 (4). Deep Brain Stimulation 
(DBS) is a surgical modality used to implant a 
electrical signal generating device; used to send its 
output to “brain areas responsible for body 
movements”. Electrodes are placed deep in the brain 
and are connected to a stimulator component. Similar 
to a heart pacemaker, the device uses electric pulses to 
regulate brain activity. 
The way in which DBS acts has not been 
completely known yet. Many theories in explaining 
effects on basal ganglia and connected circuits have 
been proposed (2). 
The main criteria for DBS Indication for GTS 
patients are almost clinical severe tic and significant 
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symptoms, even on multi different drugs prescriptions 
(5): 
 alpha adrenergic agonists 
 dopamine antagonists 




A thirty-one years old male (77 kg, 178 cm) was 
admitted to the neurosurgery ward with diagnosis of 
Gilles De La Tourette syndrome. An informed consent 
form from publication of the study was obtained for the 
patient; the process of case presentatin was approved 
by Institutional Research Ethics Committee, Research 
Deputy, SBMU, Tehran, Iran; IRB ethics code: 
IR.SBMU.RETECH.REC.1399.361. 
He was taking medication for GDT for 23 years 
but with no improvement in his symptoms and still had 
facial and ocular tics. His medication included 
Aripiprazole, pimozide, buspirone, clomipramine, 
citalopram, phenytoin, Desmopressin and Lithium. 
The patient had DI (Diabetes insipidus) in his history 
probably due to lithium use. The patient’s 
consciousness and body temperature (37.1°C) was 
normal. Physical examination showed normal cranial 
nerve function and normal upper & lower motor tone 
and force and other systems were also normal. He had 
normal vital signs. The cardiology consultation and 
echocardiography was reported within the normal 
range with left ventricular ejection fraction of 55%. 
The patient underwent implanting DBS surgery and 
battery implantation in two steps with two weeks 
interval. 
Anesthetic Implications: The patient was scheduled 
for surgery to implant DBS under general anesthesia. 
Basic and some of the advanced monitoring devices 
including electrocardiogram, heart rate, Noninvasive 
and invasive blood pressure monitoring, peripheral 
pulse oximetry, cerebral oximetry, anesthesia depth 
(using BIS: Bispectral Index) and electromyography 
were instituted. Anesthesia management included 
Fentanyl (200 μg), Midazolam (1 mg), Lidocaine (100 
mg) and Propofol (100 mg). Atracurium was 
administered (50 mg) and then orotracheal intubation 
was done. Metoclopramide prescribed for 
Postoperative nausea and vomiting prevention. 
Anesthesia maintenance included Propofol 
infusion (4-6 mg/kg/h), Oxygen plus air (50/50; 3 liters 
each) and Atracurium bolus doses of 5 mg as needed. 
Keeping end tidal CO2 (ETCO2) at 30-35 mm Hg, the 
patient was observed in a sophisticated approach 
considering the hemodynamic fluctuation and 
maintenance of adequate depth of anesthesia (BIS: 40-
60). Phenylephrine, epinephrine, atropine, TNG, 
labetalol and sodium bicarbonate were available to 
treat hemodynamic disturbances if happens 
intraoperatively. Indirect medications for increasing 
BP (ephedrine) were avoided due to the concomitant 
use of Dopaminergic agonist agents. Aripiprazole 
affects renal function; Lithium induces Diabetes 
insipidus, hyponatremia, and other electrolyte 
imbalances, so fluid therapy was modified and renal 
function profile and electrolytes were checked before, 
during and after the surgical procedure.  
Phenytoin prolongs QT interval, which make 
cardiac monitoring more important, and avoidance of 
other medication with QT prolongation as if 
Ondansetron is mandatory. 
Surgical procedure ended after 45 minutes. The 
muscle relaxant (Atracurium) was reversed with 
Neostigmine and atropine, the patient was extubated 
uneventfully, and patient was discharged after 3 days 
without neurological deficits. 
Discussion 
Patients with Gilles de la Tourette syndrome 
due to nature of the disease and their medications may 
be a challenge to the anesthesiologist. The cause and 
symptoms may be due to central dopaminergic 
hyperactivity or anomalous dopamine 
neurotransmission. Haloperidol, olanzapine, 
risperidone, clonazepam, pimozide, calcium channel 
blocker, SSRI (selective serotonin reuptake inhibitors) 
and penfluridol may descried for their treatment (6). 
The anesthesiologist should consider nature of 
the GDT complications and all medications, which 
used by patient that might affect anesthetic agents dose 
adjustment, fluid therapy and required extra 
monitoring. Each medication they receive such as 
Dopaminergic receptor inhibitors (Aripiprazole and 
Pimozide) or alpha-adrenergic antagonist (Pimozide) 
require anesthetic agent’s dose adjustment and more 
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consideration than usual. 
Intraoperative events like hypertension are 
common complications that can be correlated to poor 
perioperative patients’ anxiety control or agitation 
during the procedure; even more, they can be 
secondary to other events like uncontrolled 
intraoperative hypertension that might lead to 
intracranial bleeding (7). Arterial blood pressure 
monitoring can show beat-to-beat blood pressure 
variation and is useful to prevent Blood Pressure 
fluctuation’s adverse consequence.  
According to their medications, post-operative 
considerations for PONV and pain management are 
important. Metoclopramide with potent dopaminergic 
blocking effects, is a common choice as antiemetic 
agent (8). Metoclopramide is a selective D2 antagonist 
while most of the antipsychotic medications are D1 and 
D2 antagonists receptors that could clarify the helpful 
antiemetic effects of metoclopramide in GTS (6).  
Conclusion 
Our main purpose of this case report was to 
review general goal and features of perioperative 
management of Gilles De La Tourette Syndrome; 
including throughout the surgery and during 
anesthesia. Anesthesiologist must not only consider the 
innate features of the disease but also more 
importantly, be cautious about perioperative drug 
remedies administered to the patient and the potential 
untoward interactions with anesthetic drugs. 
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